Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cogstate Ltd ( (AU:CGS) ).
Cogstate Ltd has announced the issuance of 300,000 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure, potentially impacting its market positioning and providing new opportunities for stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd operates in the healthcare industry, focusing on providing cognitive assessment services and technologies. The company is known for its innovative solutions that aid in the measurement of brain health, serving markets such as clinical trials, academic research, and healthcare providers.
Average Trading Volume: 92,916
Technical Sentiment Signal: Buy
Current Market Cap: A$273.3M
For detailed information about CGS stock, go to TipRanks’ Stock Analysis page.